Your browser doesn't support javascript.
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
Wang, Zijun; Muecksch, Frauke; Schaefer-Babajew, Dennis; Finkin, Shlomo; Viant, Charlotte; Gaebler, Christian; Hoffmann, Hans- Heinrich; Barnes, Christopher O; Cipolla, Melissa; Ramos, Victor; Oliveira, Thiago Y; Cho, Alice; Schmidt, Fabian; Da Silva, Justin; Bednarski, Eva; Aguado, Lauren; Yee, Jim; Daga, Mridushi; Turroja, Martina; Millard, Katrina G; Jankovic, Mila; Gazumyan, Anna; Zhao, Zhen; Rice, Charles M; Bieniasz, Paul D; Caskey, Marina; Hatziioannou, Theodora; Nussenzweig, Michel C.
  • Wang Z; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Muecksch F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Schaefer-Babajew D; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Finkin S; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Viant C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gaebler C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Hoffmann HH; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Barnes CO; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Cipolla M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Oliveira TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Cho A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Schmidt F; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Da Silva J; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Bednarski E; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Aguado L; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Yee J; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Daga M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Turroja M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Millard KG; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Jankovic M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gazumyan A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Zhao Z; Howard Hughes Medical Institute, New York, NY, USA.
  • Rice CM; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
  • Bieniasz PD; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Caskey M; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
  • Hatziioannou T; Howard Hughes Medical Institute, New York, NY, USA. pbieniasz@rockefeller.edu.
  • Nussenzweig MC; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. mcaskey@rockefeller.edu.
Nature ; 595(7867): 426-431, 2021 07.
Article in English | MEDLINE | ID: covidwho-1267998
Semantic information from SemMedBD (by NLM)
1. Immune response PROCESS_OF Persons
Subject
Immune response
Predicate
PROCESS_OF
Object
Persons
2. Immune response PRODUCES Antibodies
Subject
Immune response
Predicate
PRODUCES
Object
Antibodies
3. Immune response PROCESS_OF Persons
Subject
Immune response
Predicate
PROCESS_OF
Object
Persons
4. Immune response PRODUCES Antibodies
Subject
Immune response
Predicate
PRODUCES
Object
Antibodies
ABSTRACT
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies1,2. Here we report on a cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 and 12 months after SARS-CoV-2 infection, 41% of whom also received mRNA vaccines3,4. In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable between 6 and 12 months after infection. Vaccination increases all components of the humoral response and, as expected, results in serum neutralizing activities against variants of concern similar to or greater than the neutralizing activity against the original Wuhan Hu-1 strain achieved by vaccination of naive individuals2,5-8. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in the variants of concern4,9. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand markedly after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03696-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study Topics: Vaccines / Variants Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: English Journal: Nature Year: 2021 Document Type: Article Affiliation country: S41586-021-03696-9